IN8bio, Inc. - רווח למניה בשנים עשר החודשים האחרונים INAB
The development of IN8bio, Inc. (INAB) relies on the safety and recognition of brain and blood oncology treatments. The rolling trailing twelve-month earnings per share shows a pivot driven by the outsourcing of trials to external centers and the implementation of innovative gamma-delta T-cell therapy. The value of -1.24 reflects this status, confirming the company's current level of financial stability on this chart.
פילוחי מדדים ואנליטיקה של חברת IN8bio Inc. (INAB)
Developing cancer cell therapy requires the management of IN8bio, Inc. (INAB) to maintain maximum efficiency in resource allocation. The EPS TTM metric measures the final profit allocated per security, excluding distortions caused by changes in the volume of issuance. For the investor, this calculation serves as a filter for the business's real yield. Analyzing the net income per share over the last 12 months allows for an assessment of the biotech's financial stability. The price action on this chart determines the fundamental value of a stake in the company.
